NSE · SYNCOMF · Pharmaceuticals
Syncom Formulations (India) Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹134 Cr with net profit ₹25 Cr — a 18.34% net margin, versus 16.46% the period before.
Shareholding
As of 2026-06-30
- Promoter50.57%
- Public49.08%
- FII0.35%
- DII0%
4,22,114 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.85× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #49 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Syncom Formulations (India) Ltd.(this company) | ₹1,242 Cr | 48.93 | 2.99 | 18.42% | 15.62% |
AI analysis
AI-generated · google/gemini-2.5-flashSyncom Formulations (India) Ltd., with a market capitalization of Rs 1276 Cr, reported annual revenue of Rs 482.45 Cr and an EPS of Rs 0.52. The company's total debt-to-equity ratio is 0.12.
Positives
- +The company's Return on Capital Employed (ROCE) is 24.46%.
- +Debt-to-equity ratio is low at 0.12.
- +Promoter holding is 50.5689%, indicating significant insider ownership.
Negatives
- −No dividend yield information is disclosed.
- −The company has not disclosed quarterly results since March 2026.
- −The profit margin is not available in the provided data.
Financial Performance
Syncom Formulations reported a total revenue of Rs 482.45 Cr. The net profit on an annual basis is not provided. Quarterly revenue for March 2026 was Rs 135.41 Cr, with a net profit of Rs 25.17 Cr. This follows December 2025 revenue of Rs 115.14 Cr and net profit of Rs 18.91 Cr.
Profitability & Returns
The company has a Return on Equity (ROE) of 15.6% and a Return on Capital Employed (ROCE) of 24.46%. The earnings per share (EPS) for the latest period is Rs 0.52. The Price to Earnings (PE) ratio stands at 31.63.
Balance Sheet
Syncom Formulations has a book value of Rs 3.62 per share. The debt-to-equity ratio is 0.12, indicating relatively low leverage. Specific details regarding total assets or liabilities are not available within the provided data.
Ownership & Pledges
As of June 30, 2026, promoter holding in Syncom Formulations stood at 50.5689%. Public shareholders held 49.0796% of the company. Foreign institutional investors (FIIs) held 0.349%, and Domestic Institutional Investors (DIIs) held 0.0025%. There are no shares pledged by the promoters.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Syncom Formulations (India) Ltd.share price & fundamentals